剂量速率对瘤微环境的影响使用平坦化无波束
M T Yilmaz1, A Gok2, M E Gedik3
1Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey.
概括
在临床前黑色素瘤模型中,不同剂量速率的平平无光束 (FFF) 并没有影响瘤生长,DNA损伤或瘤微环境 (TME). 需要进一步验证以了解新的辐射技术.
科学领域:
- 辐射瘤学 辐射瘤学
- 癌症生物学 癌症生物学
- 临床前研究 临床前研究
背景情况:
- 放射治疗的进步包括平整无波器 (FFF) 束.
- 研究FFF光束高剂量速率对生物的影响至关重要.
研究的目的:
- 为了确定不同剂量速率的FFF光束是否会影响瘤微环境 (TME).
- 为了测试这样的假设,即现代线性加速器的不同剂量率具有不同的生物效应.
主要方法:
- 在小鼠中的B16-F10黑色素瘤综原性瘤模型.
- 放射治疗 (RT) 使用 2 Gy 和 10 Gy 的剂量,分别为 1 Gy/min, 6 Gy/min 和 14 Gy/min.
- 分析瘤体积,DNA损伤 (彗星测定),组织形态学和免疫组织化学.
主要成果:
- 在剂量率之间没有观察到瘤体积,每日生长率或血液单核细胞DNA损伤的显著差异.
- 组织形态学检查显示,剂量速率对线粒分裂或形变异没有影响.
- 在所有测试条件下,TME中的炎症,细胞密度和标志物表达是可比的.
结论:
- 在这个临床前模型中,FFF光束的不同剂量率没有影响瘤体积,DNA损伤或TME参数.
- 建议使用替代临床前设置进行进一步验证,以充分阐明新型辐射技术的生物影响.
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Dose Size and Dosing Frequency: Determination Methods
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...


